CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 325 enrolled
Drug / intervention
Nivolumab +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03377361
NCT03377361Phase 2Completed
CompareCT.gov

A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers

Bristol-Myers Squibb·interventional·Posted Dec 19, 2017·Updated Dec 3, 2025

In Brief

A Phase 2 clinical trial evaluating Nivolumab, Trametinib, and 2 other interventions for Colorectal Cancer and 3 related conditions. Completed, enrolled 325 participants across 47 sites in 10 countries.

Detailed Summary

The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
CountriesArgentina, Australia, Belgium, Canada, Chile, Czechia, Germany, Italy, Spain, United States
CollaboratorsNovartis

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 19, 2017
Enrollment StartJan 31, 2018
Primary CompletionNov 4, 2024
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 8.5 years ago

Interventions

Nivolumabbiological

Specified dose on specified days

Trametinibdrug

Specified dose on specified days

Ipilimumabbiological

Specified dose on specified days

Regorafenibdrug

Specified dose on specified days